Shionogi Receives Contract with U.S. Government Through BARDA’s Project BioShield to Enhance National Preparedness for Drug-Resistant Bacterial Threats

Shionogi & Co., Ltd. announced that Shionogi Inc., a New Jersey-based subsidiary of Shionogi, has been awarded a contract through the Biomedical Advanced Research and Development Authority’s (BARDA) Project BioShield related to Fetroja^® (cefiderocol) as a critical countermeasure against difficult-to-treat Gram-negative bacterial infections and pathogens that present a high-priority biothreat to national health security. The contract is initially funded at $119 million with multiyear options for a total of up to $482 million.